Literature DB >> 25532945

The burden of non-radiographic axial spondyloarthritis.

Annelies Boonen1, Joachim Sieper2, Désirée van der Heijde3, Maxime Dougados4, Jack F Bukowski5, Satish Valluri5, Bonnie Vlahos5, Sameer Kotak5.   

Abstract

OBJECTIVES: To identify patients earlier, new classification criteria have been introduced for axial spondyloarthritis (axSpA). Patients who satisfy the clinical or imaging criteria for axSpA in the absence of definite sacroiliac joint changes on pelvic x-rays are classified as having non-radiographic axSpA. Although the burden associated with radiographic axSpA (i.e., ankylosing spondylitis) has been extensively studied, the impact of non-radiographic disease is not well understood. The purpose of this review is to provide an overview of the burden of illness in non-radiographic axSpA, including epidemiology and effects on patients׳ functioning and health-related quality of life (HR-QoL).
METHODS: A PubMed search was performed using relevant key words (e.g., "spondyloarthritis," "ankylosing spondylitis," "epidemiology," and "quality of life") to examine literature published from 2003 to 2013.
RESULTS: Studies conducted to date suggest that radiographic progression is detected in approximately 10% of patients with non-radiographic axSpA over 2 years. Differences between patients with non-radiographic and radiographic axSpA were found in age, symptom duration, and gender distribution. Although less inflammation (i.e., lower C-reactive protein levels and less spinal inflammation on MRI) and less impairment in spinal mobility are observed in non-radiographic than in radiographic axSpA, the 2 conditions pose a similar burden in terms of disease activity, physical function, HR-QoL impairment.
CONCLUSIONS: Patients with non-radiographic axSpA are more frequently female. Although patients with non-radiographic axSpA have shorter disease duration and lack radiological changes, they demonstrate a substantial burden of illness, with self-reported disease activity and functional impairments comparable to those found in patients with radiographic disease.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Ankylosing spondylitis; Burden of illness; Cost, work productivity; Disease activity; Epidemiology; Non-radiographic axial spondyloarthritis; Physical function; Quality of life

Mesh:

Year:  2014        PMID: 25532945     DOI: 10.1016/j.semarthrit.2014.10.009

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  40 in total

Review 1.  Prevalence and factors associated with disturbed sleep in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review.

Authors:  Shaaron Leverment; Emily Clarke; Alison Wadeley; Raj Sengupta
Journal:  Rheumatol Int       Date:  2016-10-28       Impact factor: 2.631

2.  Gait as predictor of physical function in axial spondyloarthritis: the prospective longitudinal FOLOMI (Function, Locomotion, Measurement, Inflammation) study protocol.

Authors:  Julie Soulard; Nicolas Vuillerme; Philippe Gaudin; Laurent Grange; Athan Baillet; Jean-Luc Cracowski; Robert Juvin; Jacques Vaillant
Journal:  Rheumatol Int       Date:  2019-08-07       Impact factor: 2.631

Review 3.  2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.

Authors:  Michael M Ward; Atul Deodhar; Lianne S Gensler; Maureen Dubreuil; David Yu; Muhammad Asim Khan; Nigil Haroon; David Borenstein; Runsheng Wang; Ann Biehl; Meika A Fang; Grant Louie; Vikas Majithia; Bernard Ng; Rosemary Bigham; Michael Pianin; Amit Aakash Shah; Nancy Sullivan; Marat Turgunbaev; Jeff Oristaglio; Amy Turner; Walter P Maksymowych; Liron Caplan
Journal:  Arthritis Care Res (Hoboken)       Date:  2019-08-21       Impact factor: 4.794

4.  Reliability and validity of the Turkish Version of Arthritis Research UK Musculoskeletal Health Questionnaire.

Authors:  Yasemin Akkubak; Bahar AnaforoĞlu KÜlÜnkoĞlu
Journal:  Arch Rheumatol       Date:  2019-11-06       Impact factor: 1.472

5.  The relationship between central sensitization and disease activity, quality of life, and sleep quality among patients with axial spondyloarthritis.

Authors:  Ilknur Aykurt Karlıbel; Meliha Kasapoğlu Aksoy
Journal:  Ir J Med Sci       Date:  2022-02-28       Impact factor: 1.568

Review 6.  Effectiveness of thalidomide for ankylosing spondylitis: a meta-analysis of randomized controlled trials in China.

Authors:  Dongsen Wang; Xuemei Hu; Xuan Yin; Chunying Cui; Xue Yang; Yuqing Li; Guoyong Ding; Qingjian Wu
Journal:  Clin Rheumatol       Date:  2022-05-30       Impact factor: 3.650

Review 7.  Evolving "Diagnostic" Criteria for Axial Spondyloarthritis in the Context of Anterior Uveitis.

Authors:  James T Rosenbaum
Journal:  Ocul Immunol Inflamm       Date:  2016-04-12       Impact factor: 3.070

8.  Musculoskeletal ultrasound for ankylosing spondylitis: A systematic review and meta-analysis.

Authors:  Lin Zhu; Peng Chen; Xuanjing Sun; Shuo Zhang
Journal:  Medicine (Baltimore)       Date:  2021-05-07       Impact factor: 1.889

9.  2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.

Authors:  Michael M Ward; Atul Deodhar; Lianne S Gensler; Maureen Dubreuil; David Yu; Muhammad Asim Khan; Nigil Haroon; David Borenstein; Runsheng Wang; Ann Biehl; Meika A Fang; Grant Louie; Vikas Majithia; Bernard Ng; Rosemary Bigham; Michael Pianin; Amit Aakash Shah; Nancy Sullivan; Marat Turgunbaev; Jeff Oristaglio; Amy Turner; Walter P Maksymowych; Liron Caplan
Journal:  Arthritis Rheumatol       Date:  2019-08-22       Impact factor: 15.483

10.  Costs of early spondyloarthritis: estimates from the first 3 years of the DESIR cohort.

Authors:  Stephanie Harvard; Daphne Guh; Nick Bansback; Pascal Richette; Maxime Dougados; Aslam Anis; Bruno Fautrel
Journal:  RMD Open       Date:  2016-04-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.